
Opinion|Videos|February 14, 2025
Financial and Operational Considerations of Implementing Biosimilars
A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost benefits when weighing potential savings against the operational complexities of managing multiple products.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do payer contracts and reimbursement policies influence your biosimilar adoption decisions?
- How do you balance potential savings from biosimilars against operational costs of managing multiple products?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
2
FDA approves first treatment for chronic hepatitis D virus
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5





















